Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus chemotherapy alone (CT) in first-line metastatic non–small-cell lung cancer (mNSCLC). METHODS: Patients (n = 1,013) with EGFR/ALK wild-type m...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Melissa L., Cho, Byoung Chul, Luft, Alexander, Alatorre-Alexander, Jorge, Geater, Sarayut Lucien, Laktionov, Konstantin, Kim, Sang-We, Ursol, Grygorii, Hussein, Maen, Lim, Farah Louise, Yang, Cheng-Ta, Araujo, Luiz Henrique, Saito, Haruhiro, Reinmuth, Niels, Shi, Xiaojin, Poole, Lynne, Peters, Solange, Garon, Edward B., Mok, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937097/
https://www.ncbi.nlm.nih.gov/pubmed/36327426
http://dx.doi.org/10.1200/JCO.22.00975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937097/
https://www.ncbi.nlm.nih.gov/pubmed/36327426
http://dx.doi.org/10.1200/JCO.22.00975

Ejemplares similares